PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
R&D reduction while AGEN shows 168.69% growth. Joel Greenblatt would examine competitive risk.
-6.73%
G&A reduction while AGEN shows 46.09% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
55.79%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
-5.86%
Operating expenses reduction while AGEN shows 46.09% growth. Joel Greenblatt would examine advantage.
-5.86%
Total costs reduction while AGEN shows 122.95% growth. Joel Greenblatt would examine advantage.
-72.88%
Interest expense reduction while AGEN shows 42.50% growth. Joel Greenblatt would examine advantage.
55.79%
D&A growth less than half of AGEN's 2747.43%. David Dodd would verify if efficiency is sustainable.
-143.43%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
5.86%
Operating income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-101.24%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-142.73%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-72.88%
Both companies reducing tax expense. Martin Whitman would check patterns.
-142.73%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-120.58%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-120.58%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
10.21%
Share count reduction below 50% of AGEN's 14.56%. Michael Burry would check for concerns.
10.21%
Diluted share reduction below 50% of AGEN's 14.56%. Michael Burry would check for concerns.